

Drug Candidate	Phase	Mechanism	Route of Administration	Sponsor	Study Location	ClinicalTrials.gov Identifier
BMS-981164	1	biologic (anti-IL31 monoclonal antibody)	Injection	Bristol-Myers Squibb	Non-US	NCT01614756
CNTO 7160	1		Injection	Janssen Research & Development, LLC	Non-US	NCT02345928
E6005	1	PDE4 inhibitor	Topical	Eisai Co., Ltd.	Non-US	NCT01461941
FURESTEM-AD	1	Mesenchymal stem cells	Injection	Kang Stem Biotech Co., Ltd.	Non-US	NCT01927705
OPA-15406	1	PDE-4 inhibitor	Topical	Otsuka Pharmaceutical Co., Ltd.	Non-US	NCT02334787
Sodium Hypochlorite Solution	1	antimicrobial	Topical	Makati Medical Center	Non-US	NCT02241174
XmAb#7195	1	biologic	Injection	Xencor, Inc.	US	NCT02148744
Treatment of Chronic Itch with Oral Clonidine & Oral Naltrexone	1	Clonidine: reduces sympathetic system outflow. Naltrexone: opioid receptor antagonist.	Oral	University of Minnesota	US	NCT02268448
GSK2894512 Cream	1	Non-steroidal anti-inflammatory	Topical	GlaxoSmithKline	Non-US	NCT02466152
LEO 32731	1	Inhibits secretion of TNF-a, IFN-gamma, and IL-5 but increases anti-inflammatory IL-10.	Topical	LEO Pharma	Non-US	NCT02496546
Pimecrolimus 1% vs Betamethasone dipropionate 0.05% vs Clobetasol propionate 0.05% vs Glaxal Base cream vehicle	1		Topical	LEO Pharma	Non-US	NCT02376049
AM1030-CREAM	1 & 2	5-HT2B receptor antagonist	Topical	AnaMar AB	Non-US	NCT02379910
Apremilast (CC-10004)	2	PDE-4 inhibitor	Oral	Celgene Corporation	US/ Non-US	NCT02087943
AQX-1125	2	Activates SHIP1 pathway	Oral	Aquinox Pharmaceuticals, Inc.	Non-US	NCT02324972
CIM331	2	Anti-IL-31 receptor	Injection	Chugai Pharmaceutical	US	NCT01986933
CT327	2	Anti-Pruritic	Topical	Creabilis SA	Non-US	NCT01808157
DS107G	2	Derivative of an omega-6 fatty acid	Oral	Dignity Sciences, LTD	US/ Non-US	NCT02211417
Dupilumab and Immune Responses	2	Biologic IL-4R Antibody	Injection	Regeneron Pharmaceuticals	US	NCT02407756
IgE specific Immunoabsorption	2	removal of IgE		Universitaire Ziekenhuizen Leuven	Non-US	NCT02365246
ILV-094	2	anti- IL-22	Injection	Rockefeller University	US	NCT01941537
KHK4577	2	Interventional	Oral	Kyowa Hakko Kirin Company, Limited	Non-US	NCT02004119
KM110329	2	Dietary supplement	Oral	Kyunghee University Medical Center	Non-US	NCT01692093
MRX-6 Cream 2%	2	Anti-Inflammatory	Topical	Celsus Therapeutics PLC	Non-US	NCT02031445
OC000459	2	DP2 antagonist	Oral	Atopix Therapeutics, Ltd.	Non-US	NCT02002208
SB011	2	Cleaves GATA-3 mRNA	Topical	Sterna Biologicals GmbH & Co. KG	Non-US	NCT02079688
QAW039	2	(PGD2), DP2 (CRTH2)	Oral	Noavrtis Pharmaceuticals	Non-US	NCT01785602
Tralokinumab	2	anti-IL13	Injection	MedImmune LLC	US	NCT02347176
VLY-686	2	anti-pruritic	Oral	Vanda Pharmaceuticals	Non-US	NCT02004041
Omiganan (CLS001)	2	Cationic antimicrobial peptide	Topical	Cutanea Life Sciences	Non-US	NCT02456480
ZPL-3893787	2	Histamine H4 receptor antagonist	Oral	Ziarco Pharma Ltd	Non-US	NCT02424253
Asimadoline (To tx pruritis associated with AD)	2	Selective kappa-opioid receptor agonist	Oral	Tioga Pharmaceuticals		NCT02475447
Lebrikizumab	2	anti-IL13	Injection	Hoffmann-La Roche	US/Non-US	NCT02340234
Device: Immunoabsorptions with an IgE-specific adsorption column	2	Removal of IgE after apheresis of blood	Device	Universitaire Ziekenhuizen Leuven	Non-US	NCT02365246
Q301	2	anti-inflammatory	Topical	Qurient Co., Ltd	US	NCT02426359
VPD-737 for Prurigo Nodularis	2	Neurokinin-1 (NK1) Receptor Antagonist	Oral	Tigercat Pharma, Inc.	Non-US	NCT02196324
Moisturizer + Subject's Own Antimicrobial Bacteria	2	Decrease S. aureus colonization and increase colonization by protective Staph species	Topical	Richard Gallo, University of California, S	US	NCT02144142
Ustekinumab	2	anti-IL12/23	Injection	Rockefeller University	US	NCT01806662
Amino Acid Moisturizing Cream/Desonide Cream	3	hydrates skin/anti-inflammatory	Topical	NeoStrata Company, Inc.	US	NCT02286700
AN2728 Topical Ointment, 2%	3	PDE-4 inhibitor	Topical	Anacor Pharmaceuticals, Inc.	US	NCT02118792
Clemastine Fumarate + Dexamethasone	3	anti-inflammatory	Topical	EMS	Non-US	NCT01257061
Dupilimab Monotherapy Efficacy and Safety	3	biologic IL-4R Antibody	Injection	Regeneron Pharmaceuticals	US	NCT02277743
Dupilumab + Topical Corticosteroids Long-term Safety	3	biologic IL-4R Antibody	Injection	Regeneron Pharmaceuticals	US	NCT02260986
Holly Mangrove Shower Gel	3	Improves skin barrier function	Topical	Mahidol University	Non-US	NCT02178215